EP Patent

EP1321518A1 — Modified MEK1 and MEK2, crystal of a peptide: ligand: cofactor complex containing such modified MEK1 or MEK2, and methods of use thereof

Assigned to Warner Lambert Co LLC · Expires 2003-06-25 · 23y expired

What this patent protects

Modified MEK1 peptides and modified MEK2 peptides, polynucleotides encoding those peptides, and methods for purifying the peptides and crystallizing them as peptide: cofactor: ligand complexes have been discovered. The three-dimensional structures of MEK1 peptide and MEK2 peptide…

USPTO Abstract

Modified MEK1 peptides and modified MEK2 peptides, polynucleotides encoding those peptides, and methods for purifying the peptides and crystallizing them as peptide: cofactor: ligand complexes have been discovered. The three-dimensional structures of MEK1 peptide and MEK2 peptide, including the cofactor-and ligand-binding pockets, and uses of this information, for example, in molecular replacement and the modification, design and screening of compounds that may associate with MEK1, MEK2, or peptides structurally related thereto, have also been discovered.

Drugs covered by this patent

Patent Metadata

Patent number
EP1321518A1
Jurisdiction
EP
Classification
Expires
2003-06-25
Drug substance claim
No
Drug product claim
No
Assignee
Warner Lambert Co LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.